Get the Stockscreener App
2.56
6.23%
-0.17
Inmune Bio Inc stock is traded at $2.56, with a volume of 965.09K.
It is down -6.23% in the last 24 hours and up +22.49% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$2.73
Open:
$2.555
24h Volume:
965.09K
Relative Volume:
0.36
Market Cap:
$60.38M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-1.5329
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
-5.54%
1M Performance:
+22.49%
6M Performance:
-74.80%
1Y Performance:
-67.64%
1-Day Range:
$2.45
$2.64
1-Week Range:
$2.45
$3.244
52-Week Range:
$1.89
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
2.56 | 74.37M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Is INmune Bio Inc. stock overvalued or undervaluedAI Powered Picks For Fast Growth - jammulinksnews.com
INmune Bio Inc. May Be Forming Higher Low — Chartwatchers AlertReal Trader Watchlist of Hot Stocks Released - metal.it
Is INmune Bio Inc. a growth stock or a value stockFree Stock Forecasts For 2025 - jammulinksnews.com
What makes INmune Bio Inc. stock price move sharplyStock Market Opportunities For Every Investor - jammulinksnews.com
Price Channel Expanding on INmune Bio Inc.’s ChartOversold Bounce Stock Play Ideas Gain Attention - metal.it
Inmune Bio Inc. shares fall 1.83% after-hours as the company prepares to report Q2 2025 financial results. - AInvest
INmune Bio Inc. to Host Conference Call on August 7, 2025 for Q2 Results and Corporate Update - Quiver Quantitative
INmune Bio Announces Q1 Earnings Call on August 7th, 2025 at 4:30 PM EDT. - AInvest
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th - The Manila Times
INmune Bio to Present Q2 2025 Financial Results and Key Clinical-Stage Updates on August 7 - Stock Titan
When is INmune Bio Inc. stock expected to show significant growthReal Time Guidance For 2025 - jammulinksnews.com
Inmune Bio shares fall 2.53% premarket after announcing a video detailing MINDFuL trial findings. - AInvest
INmune Bio Releases Video on Alzheimer’s Trial Results - TipRanks
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference - The Manila Times
INmune Bio To Share New Alzheimer's Trial Results On YouTube After Major Conference Reveal - 富途牛牛
Breakthrough in Alzheimer's Treatment: Phase 2 Trial Reveals XPro Drug's Impact on Cognitive Decline - Stock Titan
How INmune Bio Inc. stock performs during market volatilityROI Driven Equity Selection With Safety Emphasized - metal.it
Trend Reversal Possible in INmune Bio Inc. Charts IndicateSwing Trade Entry With Volume Triggers Released - metal.it
Is INmune Bio Inc. Stock a Good Fit for Conservative InvestorsDaily Volume Spike Trading Signals Detected - metal.it
Alzheimer’s Breakthrough: INmune Bio’s XPro Trial Shows Promise in Subpopulation - StocksToTrade
How does INmune Bio Inc. compare to its industry peersDaily Trading Ideas For Fast Growth - jammulinksnews.com
How does INmune Bio Inc. generate profit in a changing economyBuild wealth faster with high-performing stocks - jammulinksnews.com
INmune Bio Stock Soars 19.56% on Clinical Trial Success - AInvest
INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge? - Benzinga
What are analysts’ price targets for INmune Bio Inc. in the next 12 monthsAchieve breakthrough gains with smart trades - jammulinksnews.com
How many analysts rate INmune Bio Inc. as a “Buy”Achieve breakthrough profits with expert advice - jammulinksnews.com
New Product Launches: Will They Boost INmune Bio Inc. Stock in 2025Best Stocks for Capital Safety - metal.it
What institutional investors are buying INmune Bio Inc. stockSuperior return velocity - jammulinksnews.com
Inmune Bio Reveals Promising XPro™ Trial Results - The Globe and Mail
Why INmune Bio Inc. stock attracts strong analyst attentionFree Stock Selection with 300% Return - metal.it
What analysts say about INmune Bio Inc. stockConsistently high returns - PrintWeekIndia
Is INmune Bio Inc. a good long term investmentOutstanding capital growth - PrintWeekIndia
INmune Bio Shares Plunge After Alzheimer's Trial Misses Target - Finimize
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at - GuruFocus
INmune Bio Inc. Stock Analysis and ForecastSuperior risk-adjusted returns - PrintWeekIndia
What drives INmune Bio Inc. stock priceSignificant capital appreciation - PrintWeekIndia
INmune Bio announces analyses from Phase 2 MINDFuL trial, endpoint not met - TipRanks
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference - The Manila Times
INmune Bio to present additional Phase 2 Alzheimer’s trial data By Investing.com - Investing.com Canada
INmune Bio to present additional Phase 2 Alzheimer’s trial data - Investing.com
Inmune Bio Inc. shares rise 3.15% premarket after ABIVAX Société Anonyme reports positive Phase III ABTECT-1 Induction trial results. - AInvest
Is INMB more suitable for short-term or long-term investment? - AInvest
When (INMB) Moves Investors should Listen - news.stocktradersdaily.com
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):